Calibr-Skaggs Institute for Innovative Medicines, the nonprofit arm of Scripps Research focusing on drug development, has revealed an expansion in its collaboration with AbbVie (NYSE: ABBV). This extension aims to further investigate Calibr-Skaggs' switchable CAR-T (sCAR-T) platform concerning solid tumor indications and autoimmune diseases.

Calibr-Skaggs and leader of the sCAR-T program, expressed enthusiasm, stating, "The performance of our switchable CAR-T cell platform has surpassed our expectations in these early clinical findings." Young added, "We highly value AbbVie's continued partnership in exploring this platform's potential in solid tumors and autoimmune conditions. We believe this technology could significantly impact solid tumors, an area where conventional CAR-T therapies have shown limited efficacy."

Conventional CAR-T cell therapies involve modifying a patient's T cells to target cancer cells specifically, then reintroducing them into the patient's body to eliminate cancer cells. However, broader application of traditional CAR-T treatments has been constrained by safety concerns and limited responses against solid tumor cancers. Calibr-Skaggs' sCAR-T approach seeks to address these challenges by regulating the activation of modified CAR-T cells using a unique antibody-based "switch." This switch binds to a tumor antigen and the sCAR-T cell component intermittently, aiming to control their activation. Additionally, this novel mechanism may enhance effectiveness in treating solid tumors.

Given the heterogeneity of patients, cancers, and treatment responses, utilizing a switchable molecule could enable physicians to tailor treatments to individual patient needs, whether adjusting to symptoms or maintaining treatment.

AbbVie, emphasized their commitment to innovation in tackling existing treatment challenges in oncology and immunology. Sedgwick stated, "Unlike traditional CAR-T cell therapies, Calibr-Skaggs' innovative approach may offer enhanced control and precision for activating CAR-Ts, potentially reducing adverse effects. We anticipate collaborating with Calibr-Skaggs to further explore this promising avenue for next-generation treatments."

AbbVie will provide Calibr-Skaggs with an upfront license fee and exclusive access to the switchable CAR-T platform for up to five years. AbbVie also retains the option to license existing cell therapy programs under development by Calibr-Skaggs for hematological and solid tumors, including the lead program. Furthermore, AbbVie has the opportunity to investigate the applicability of sCAR-Ts in autoimmune diseases. Calibr-Skaggs stands to receive milestone payments and royalties based on success.

 

Source: prnewswire.com

Report Abuse